Login or sign up
For business

Caldan Therapeutics

4.0· 9 reviews
Average ratingGreat
4.0/ 5

Based on 9 reviews

533%
433%
333%
20%
10%
Ask AI

Ask Trustburn about Caldan Therapeutics

Based on 9 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Lorianne Garofalo
Reviews 1

Caldan Therapeutics is a company that truly understands the needs of its customers. Their products are innovative and highly effective. I have seen remarkable results after using their therapeutic solutions. I highly recommend Caldan Therapeutics to anyone in need of reliable and efficient products.

Chris Hannigan
Reviews 1

I have been a customer of Caldan Therapeutics for the past year and I must say that their products are outstanding. The quality is top-notch and the customer service is exceptional. I would highly recommend Caldan Therapeutics to anyone looking for reliable and effective therapeutic solutions.

Lisa Weinberg
Reviews 1

Caldan Therapeutics has exceeded my expectations in every way. Their products are effective, safe, and affordable. The customer service team is always helpful and responsive. I highly recommend Caldan Therapeutics to anyone in need of high-quality therapeutic solutions.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Caldan Therapeutics

Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications.

The spinout opportunity has arisen from a long term collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU).

Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.